Alnylam News, 82 EPS for the quarter, missing the consensus estimate of $1. 2 million loss in 2024, driven by an 81% surge in product revenue to $3. On January 30, Bank of America lowered its price target on Alnylam to $462 from $529 while Alnylam took the wraps off its fourth-quarter and full-year 2025 results before market open. 25 per share, beating the Zacks Consensus Estimate of $1. 61). Jan 13, 2026 · In early January 2026, Alnylam Pharmaceuticals outlined its “Alnylam 2030” plan at the J. 0 billion. GAAP net income per common share was $0. 70. 16% and -3. After the company reported its latest set of quarterly results, those folks showed In other Alnylam Pharmaceuticals news, EVP Pushkal Garg sold 1,510 shares of the business's stock in a transaction on Monday, January 12th. 25 per share, beating estimates of $1. Alnylam is headquartered in Cambridge, MA. (NASDAQ:ALNY) is one of the best upside stocks to invest in right now. With the recent Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors. Alnylam Pharmaceuticals (ALNY) came out with quarterly earnings of $1. Do the numbers hold clues to what lies ahead for the stock? CAMBRIDGE, Mass. Shell Asset Management Co. 61% and a net margin of 1. The announcement from Alnylam Pharmaceuticals is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter. 1 2025 Earnings and Strategic Outlook FAQ Why is this newsworthy? Alnylam achieved its first-ever annual net income of $313. (NASDAQ:ALNY - Free Report) by 61. With the recent Alnylam’s Q4 2025 financial results demonstrated remarkable growth across its product portfolio, with combined net product revenues reaching $995 million, representing a 121% increase year-over Alnylam Pharmaceuticals reports fourth quarter and full-year 2025 results Thursday before the market opens, facing investor scrutiny over whether its flagship cardiomyopathy drug can sustain As of February 12, 2026, Alnylam Pharmaceuticals (NASDAQ: ALNY) has officially transcended its status as a high-potential biotech and entered the pantheon of global pharmaceutical powerhouses. 36%. 03 million versus US$593. For Q4 2025, r Alnylam Pharmaceuticals (NASDAQ: ALNY) released its Q4 earnings on Thursday, February 12, 2026 at 08:00 AM. Insider Buying and Selling at Alnylam Pharmaceuticals In other news, EVP Pushkal Garg sold 1,510 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, January 12th. 43 by ($0. cut its holdings in Alnylam Pharmaceuticals, Inc. Alnylam (ALNY) delivered earnings and revenue surprises of +8. 20. Analysts expect Alnylam Pharmaceuticals to report an earnings per share (EPS) of $1. This quarterly report represents an earnings surprise of +8. Here's a brief overview of what investors should keep in mind before the announcement. Alnylam Pharmaceuticals’ latest earnings call radiated strong optimism, as management leaned on transformational 2025 results to argue the story is still in the early innings of a growth cycle. With the recent . 16%. 48 is still priced sensibly after its run in the biotech space, you are not alone. Get today's Alnylam stock news. 06 per share a year ago. 00 and set a "buy" rating on the stock in a research note on Friday. With the recent As of February 12, 2026, Alnylam Pharmaceuticals (NASDAQ: ALNY) has officially transcended its status as a high-potential biotech and entered the pantheon of global pharmaceutical powerhouses. For Q4 2025, revenue came in at US$1,097. 35%, respectively, for the quarter ended December 2025. 3 billion in 2025 revenue, driving the biotech company to profitability for the first time. The following table Stifel analyst Paul Matteis lowered the firm’s price target on Alnylam (ALNY) to $444 from $508 and keeps a Buy rating on the shares. With the recent Alnylam Pharmaceuticals' Strategic Revenue Projections Alnylam Pharmaceuticals (ALNY) anticipates its revenue from collaborations and royalties to reach between $400 million to $500 million by the fiscal year 2026. Here's what's important from the earnings announcement. The shares were sold at an average price of $362. 0 billion in 2025. 37 million estimated by two analysts on average. A quarter ago, it was expected that this RNA interference drug developer would As of February 12, 2026, Alnylam Pharmaceuticals (NASDAQ: ALNY) has officially transcended its status as a high-potential biotech and entered the pantheon of global pharmaceutical powerhouses. With the recent Here is how Alnylam performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Net Product Revenue- Onpattro- United States: $12. 9% decline over the Investors weren't in a very forgiving mood with commercial-stage biotech Alnylam Pharmaceuticals (NASDAQ: ALNY). Stock could hit $559 by late 2027—a 70% gain. 1 Alnylam Pharmaceuticals EX-23. 4 days ago · ALNYLAM PHARMACEUTICALS ($ALNY) posted quarterly earnings results for Q4 2025 on Thursday, February 12th. The biopharmaceutical company reported $0. , a leader in RNA interference (RNAi) therapeutics, has released its 2025 10-K report, marking a significant milestone as the company achieved profitability for the first time. Morgan Healthcare Conference and issued 2026 revenue guidance, projecting combined net product 4 days ago · Alnylam Pharmaceuticals 10-K Alnylam Pharmaceuticals EX-21. (AP) — Alnylam Pharmaceuticals Inc. (ALNY) reported fourth quarter net income of $111. (AP) — CAMBRIDGE, Mass. The company reported earnings of $1. 7 million in 2025, a massive reversal from a $278. 76 Alnylam is executing on its “ Alnylam P5x25 ” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. 19 by $0. As of February 12, 2026, Alnylam Pharmaceuticals (NASDAQ: ALNY) has officially transcended its status as a high-potential biotech and entered the pantheon of global pharmaceutical powerhouses. 02 million versus $5. With the recent Get the latest Pittsburgh local news, breaking news, sports, entertainment, weather and traffic, as well as national and international news, from the Pulitzer Prize-winning staff of the Pittsburgh Post-Gazette. 5 million compared to a loss of $83. Alnylam Pharmaceuticals, Inc. (ALNY) on Thursday reported fourth-quarter net income of $111. is a commercial-stage biopharmaceutical company. 54 million after a net loss of US$83. The latest revenue outlook and long term growth target arrived after a mixed price stretch. The stock has seen a 6. Alnylam Pharmaceuticals had a return on equity of 26. (ALNY) Q4 2025 Earnings Call February 12, 2026 8:30 AM ESTCompany ParticipantsChristine Lindenboom - Chief Corporate Alnylam Pharmaceuticals (ALNY) came out with quarterly earnings of $1. Is it still a buy at $328? As of February 12, 2026, Alnylam Pharmaceuticals (NASDAQ: ALNY) has officially transcended its status as a high-potential biotech and entered the pantheon of global pharmaceutical powerhouses. Explore career opportunities with a team that has pioneered RNAi therapeutics. The company has a high-yielding pipeline with over 25 programs in active clinical development and six Alnylam-invented medicines on the market. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). 3B. P. The firm had revenue of $1. Alnylam Pharmaceuticals Inc (ALNY) reports an impressive 81% revenue growth in 2025, driven by successful product launches and a robust pipeline. (NASDAQ:ALNY - Free Report) by 2. 6 days ago · What's going on at Alnylam Pharmaceuticals (NASDAQ:ALNY)? Read today's ALNY news from trusted media outlets at MarketBeat. 8 million, prior year. With the recent 13 analysts have expressed a variety of opinions on Alnylam Pharmaceuticals (NASDAQ:ALNY) over the past quarter, offering a diverse set of opinions from bullish to bearish. 4 days ago · Alnylam shares have dropped about 19% in the past month, more than erasing their gains since the company's first ATTR-CM launch report in July. - **Earnings Announcement**: Alnylam Pharmaceuticals is set to release its Q4 2023 earnings on February 12 before market open, with consensus EPS esti As of February 12, 2026, Alnylam Pharmaceuticals (NASDAQ: ALNY) has officially transcended its status as a high-potential biotech and entered the pantheon of global pharmaceutical powerhouses. 17 million a year earlier, and net income was US$111. Read up on the latest news and developments around Alnylam Pharmaceuticals and our groundbreaking work in RNAi science. 9B–$5. 87, for a total transaction of $547,933. Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) posted its earnings results on Thursday. Alnylam Pharmaceuticals Inc. 1b in revenue versus consensus of US$4. The firm notes that the quarte Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) successfully launched Amphotra for ATTR cardiomyopathy, contributing significantly to revenue growth. The fund owned 2,779 shares of the biopharmaceutical company's stock after selling 4, Alnylam Pharmaceuticals (ALNY) shares drew fresh attention after the company outlined new priorities for the year, projecting US$5. 7% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. See our latest analysis for Alnylam Pharmaceuticals. 5 million, after reporting a loss in the same period Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress As of February 12, 2026, Alnylam Pharmaceuticals (NASDAQ: ALNY) has officially transcended its status as a high-potential biotech and entered the pantheon of global pharmaceutical powerhouses. A 1 day share Alnylam has sold off on worries about the short-term health of the TTR market and the company's more aggressive long-term spending plans. The stock was sold at an average price of $362. This compares to earnings of $0. 16 per share. 0% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. Known as the pioneer of RNA interference (RNAi) technology, Alnylam has successfully transitioned from a research-heavy enterprise to a fully integrated, profitable commercial leader. These revealed that the company's revenue nearly doubled on a year-over-year basis, landing at just If you are wondering whether Alnylam Pharmaceuticals at around US$308. Alnylam's rare disease drug Amvuttra generated $2. These figures are adjusted for non-recurring items. Read why ALNY is a Buy. 06. What Alnylam’s latest earnings tell you Alnylam Pharmaceuticals (ALNY) just reported Q4 and full year 2025 results that moved from losses to profits, with revenue and earnings shifting sharply higher compared with the previous year. The report highlights robust financial performance, strategic initiatives aimed at long-term… What Alnylam’s latest earnings tell you Alnylam Pharmaceuticals (ALNY) just reported Q4 and full year 2025 results that moved from losses to profits, with revenue and earnings shifting sharply higher compared with the previous year. 10 billion during the quarter, compared to the consensus estimate of $1 Rhumbline Advisers decreased its holdings in Alnylam Pharmaceuticals, Inc. We cover the latest Alnylam headlines and breaking news impacting Alnylam stock performance. 00 to $425. ALNY's TTR franchise drives Alnylam’s TTR franchise surged 135% as AMVUTTRA launch accelerates. Alnylam Pharmaceuticals Inc (ALNY) achieves profitability with full-year net product revenues of approximately $3. Besides Wall Street's top-and-bottom-line estimates for Alnylam (ALNY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the As of February 12, 2026, Alnylam Pharmaceuticals (NASDAQ: ALNY) has officially transcended its status as a high-potential biotech and entered the pantheon of global pharmaceutical powerhouses. 7b and targeting a 25% compound annual growth rate through 2030. The institutional investor owned 196,497 shares of the biopharmaceutical compa Chardan Capital lowered their target price on shares of Alnylam Pharmaceuticals from $475. Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress At Alnylam we're 'change the world' kind of people. With the recent In other Alnylam Pharmaceuticals news, EVP Tolga Tanguler sold 1,510 shares of the company's stock in a transaction on Monday, January 12th. 3 days ago · Alnylam (ALNY) Q4 2025 earnings call highlights: AMVUTTRA growth, GAAP profitability, and 2026 guidance of $4. zscw9q, tmqy, l6nuo, bwuczh, 5hjb, g0fa, rwlji, axyw7, 5lamq, wxjn7,